Trial Site Method Result Ozyigit et al. [95 ] Nasopharynx Retrospectively compared outcomes of SABR versus 3DCRT+/− brachytherapy. Responses were similar in both arms. However, SABR associated with lesser toxicity. Iwata et al. [96 ] Sinonasal 51 patients of post-RT recurrent sinonasal malignancies reirradiated with SABR (median dose 60 Gy). Feasible for salvage post-RT. Further innovations needed in fractionation and combination chemotherapy. Jereczek-Fossa et al. [64 ] Prostate primary or nodal SABR (median dose of 30 Gy in 4-5 Fc) for reirradiation in 34 patients. Feasible approach for isolated recurrent primary/nodal prostate cancer. Low toxicity. In-field progression in <10% cases. Dewas et al. [97 ] Uterocervical, bladder 16 patients treated with SABR (6 × 6 Fc) for reirradiation of lateral pelvic recurrences. Offers a short and well-tolerated treatment for lateral pelvic recurrences in previously irradiated patients who are otherwise not treatable. Sahgal et al. [98 ] Spine 37 patients with history of prior conventional RT and 23 patients with no prior history of RT. Reirradiation with SABR (median dose of 24 Gy in 3 Fc). 2-year overall progression free probability was 85%. No significant difference in survival or local control in patients with or without prior radiotherapy. Choi et al. [99 ] Spine Retrospective series ( Reirradiation with SABR provided 1-year LC of 73%. Time interval between prior RT and SABR was predictive of response. Sterzing et al. [100 ] Spine 2-year LC of 63%. No incidence of severe toxicity. Poltinnikov et al. [106 ] Lung 17 NSCLC patients all recurred after prior conventional RT of ≥50 Gy. SABR provided median OS of 5.5 months. 11 of 13 patients who were symptomatic with dyspnoea had improved. Kelly et al. [107 ] Lung Retrospective study ( Excellent in-field tumor control of 92% at 2-years. No grade 4-5 toxicities. Coon et al. [108 ] Lung SABR for recurrent primary lung lesions after prior RT ( 1-year LC was 92%, and 1-year OS was 67%.
